胰腺神经内分泌瘤的精准诊疗进展

doi:10.19401/j.cnki.1007-3639.2023.11.004

摘要/Abstract

摘要：

自2011年肿瘤精准医疗的概念提出后，实体肿瘤的治疗逐渐迈入以基因检测和靶向治疗为主导的精准医学时代。作为少见肿瘤，胰腺神经内分泌瘤（pancreatic neuroendocrine tumor，PanNET）的发病率逐年升高，既往以分期、分级、分化为基础的临床病理学因素作为PanNET治疗选择和预后预测的指标，没有精准标志物用于判断PanNET预后及指导其治疗药物的选择。随着临床医师对PanNET的诊断、治疗和预后预测等方面的认识更新，以及基因组学和分子检测在PanNET中的深入研究，精准医疗能否给PanNET的诊治和预后预测带来新的变革?本文通过回顾最新文献阐述PanNET精准诊疗现状。

关键词: 胰腺神经内分泌肿瘤, 精准医疗, 预后预测, 靶向治疗

Abstract:

Since the concept of precision medicine proposed in 2011, the treatment of solid tumors has entered era of precision medicine led by gene testing. As a rare tumor, the incidence rate of pancreatic neuroendocrine tumor (PanNET) is increasing gradually. In the past, clinicopathological factors such as stage and grade system were used as criteria in the diagnosis and prognostic prediction of PanNET patients, and there were few biomarkers guiding the selection of PanNET diagnosis and treatment. As the diagnosis, treatment and prognosis of PanNET have been updated these years, and genomics and molecular testing are wildly used in PanNET research, can precision bring new changes to the diagnosis, treatment and prognostic prediction of PanNET? This article reviewed the current status of PanNET precision therapy through the latest literature.

Key words: Pancreatic neuroendocrine neoplasm, Precision medicine, Prognostic prediction, Target therapy

中图分类号:

R735.9

高鹤丽, 徐近, 陈洁, 虞先濬. 胰腺神经内分泌瘤的精准诊疗进展[J]. 中国癌症杂志, 2023, 33(11): 993-1001.

GAO Heli, XU Jin, CHEN Jie, YU Xianjun. Updates on precision medicine of pancreatic neuroendocrine tumor[J]. China Oncology, 2023, 33(11): 993-1001.

参考文献 67

[1]	BECKMANN J S, LEW D. Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities[J]. Genome Med, 2016, 8(1): 134. pmid: 27993174
[2]	PARK J J H, HSU G, SIDEN E G, et al. An overview of precision oncology basket and umbrella trials for clinicians[J]. CA A Cancer J Clin, 2020, 70(2): 125-137. doi: 10.3322/caac.v70.2
[3]	SATPATHY S, JAEHNIG E J, KRUG K, et al. Microscaled proteogenomic methods for precision oncology[J]. Nat Commun, 2020, 11(1): 532. doi: 10.1038/s41467-020-14381-2 pmid: 31988290
[4]	LLOYD R V, OSAMURA R Y, KLOPPEL G, et al. WHO classification of tumours of endocrine organs[M]. 4th ed, Lyon: International Agency for Research on Cancer (IARC) Press, 2017: 11-64.
[5]	SZYBOWSKA M, METE O, WEBER E, et al. Neuroendocrine neoplasms associated with germline pathogenic variants in the homologous recombination pathway[J]. Endocr Pathol, 2019, 30(3): 237-245. doi: 10.1007/s12022-019-9569-4 pmid: 30772928
[6]	ALREZK R, HANNAH-SHMOUNI F, STRATAKIS C A. MEN4 and CDKN1B mutations: the latest of the MEN syndromes[J]. Endocr Relat Cancer, 2017, 24(10): T195-T208. doi: 10.1530/ERC-17-0243
[7]	UCCELLA S, LA ROSA S, METOVIC J, et al. Genomics of high-grade neuroendocrine neoplasms: well-differentiated neuroendocrine tumor with high-grade features (G3 NET) and neuroendocrine carcinomas (NEC) of various anatomic sites[J]. Endocr Pathol, 2021, 32(1): 192-210. doi: 10.1007/s12022-020-09660-z pmid: 33433884
[8]	BOCCHINI M, NICOLINI F, SEVERI S, et al. Biomarkers for pancreatic neuroendocrine neoplasms (PanNENs) management-an updated review[J]. Front Oncol, 2020, 10: 831. doi: 10.3389/fonc.2020.00831 pmid: 32537434
[9]	ÖBERG K, CALIFANO A, STROSBERG J R, et al. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood[J]. Ann Oncol, 2020, 31(2): 202-212. doi: S0923-7534(19)39084-2 pmid: 31959337
[10]	MAPELLI P, BEZZI C, MUFFATTI F, et al. Somatostatin receptor activity assessed by ⁶⁸Ga-DOTATOC PET can preoperatively predict DAXX/ATRX loss of expression in well-differentiated pancreatic neuroendocrine tumors[J]. Eur J Nucl Med Mol Imaging, 2023, 50(9): 2818-2829. doi: 10.1007/s00259-023-06210-7
[11]	ROZENBLUM L, MOKRANE F Z, YEH R, et al. Imaging-guided precision medicine in non-resectable gastro-entero-pancreatic neuroendocrine tumors: a step-by-step approach[J]. Eur J Radiol, 2020, 122: 108743. doi: 10.1016/j.ejrad.2019.108743
[12]	BINDERUP T, KNIGGE U, JOHNBECK C B, et al. 18F-FDG PET is superior to WHO grading as a prognostic tool in neuroendocrine neoplasms and useful in guiding PRRT: a prospective 10-year follow-up study[J]. J Nucl Med, 2021, 62(6): 808-815. doi: 10.2967/jnumed.120.244798
[13]	PRIESTLEY P, BABER J, LOLKEMA M P, et al. Pan-cancer whole-genome analyses of metastatic solid tumours[J]. Nature, 2019, 575(7781): 210-216. doi: 10.1038/s41586-019-1689-y
[14]	CAO Y N, ZHOU W W, LI L, et al. Pan-cancer analysis of somatic mutations across 21 neuroendocrine tumor types[J]. Cell Res, 2018, 28(5): 601-604. doi: 10.1038/s41422-018-0019-5 pmid: 29507395
[15]	SCARPA A, CHANG D K, NONES K, et al. Whole-genome landscape of pancreatic neuroendocrine tumours[J]. Nature, 2017, 543(7643): 65-71. doi: 10.1038/nature21063
[16]	JIAO Y C, SHI C J, EDIL B H, et al. DAXX/ATRX,MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors[J]. Science, 2011, 331(6021): 1199-1203. doi: 10.1126/science.1200609
[17]	YAMAUCHI Y, KODAMA Y, SHIOKAWA M, et al. Rb and p53 execute distinct roles in the development of pancreatic neuroendocrine tumors[J]. Cancer Res, 2020, 80(17): 3620-3630. doi: 10.1158/0008-5472.CAN-19-2232 pmid: 32591410
[18]	WHO Classification of Tumours Editorial Board. Endocrine and Neuroendocrine tumours[S/OL]. 5th ed. Lyon (France): International Agency for Research on Cancer, 2022[2023-08-11]. https://tumourclassification.larc.who.int/charpters/53.
[19]	GAO H L, LIU L, WANG W Q, et al. Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor[J]. Cancer Lett, 2018, 412: 188-193. doi: S0304-3835(17)30673-0 pmid: 29107104
[20]	WANG W Q, ZHANG W H, GAO H L, et al. A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors[J]. J Gastroenterol, 2021, 56(4): 395-405. doi: 10.1007/s00535-021-01777-0
[21]	TITAN A L, NORTON J A, FISHER A T, et al. Evaluation of outcomes following surgery for locally advanced pancreatic neuroendocrine tumors[J]. JAMA Netw Open, 2020, 3(11): e2024318.
[22]	HACKENG W M, BROSENS L A A, KIM J Y, et al. Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size[J]. Gut, 2022, 71(5): 961-973. doi: 10.1136/gutjnl-2020-322595
[23]	ALTIMARI M, ABAD J, CHAWLA A. The role of oncologic resection and enucleation for small pancreatic neuroendocrine tumors[J]. HPB, 2021, 23(10): 1533-1540. doi: 10.1016/j.hpb.2021.03.005 pmid: 33832835
[24]	CEJAS P, DRIER Y, DREIJERINK K M A, et al. Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors[J]. Nat Med, 2019, 25(8): 1260-1265. doi: 10.1038/s41591-019-0493-4 pmid: 31263286
[25]	HACKENG W M, SCHELHAAS W, MORSINK F H M, et al. Alternative lengthening of telomeres and differential expression of endocrine transcription factors distinguish metastatic and non-metastatic insulinomas[J]. Endocr Pathol, 2020, 31(2): 108-118. doi: 10.1007/s12022-020-09611-8 pmid: 32103422
[26]	HUA J, SHI S, XU J, et al. Expression patterns and prognostic value of DNA damage repair proteins in resected pancreatic neuroendocrine neoplasms[J]. Ann Surg, 2022, 275(2): e443-e452. doi: 10.1097/SLA.0000000000003884
[27]	RIZZO F M, MEYER T. Liquid biopsies for neuroendocrine tumors: circulating tumor cells, DNA, and microRNAs[J]. Endocrinol Metab Clin N Am, 2018, 47(3): 471-483. doi: 10.1016/j.ecl.2018.04.002
[28]	KHAN M S, KIRKWOOD A A, TSIGANI T, et al. Early changes in circulating tumor cells are associated with response and survival following treatment of metastatic neuroendocrine neoplasms[J]. Clin Cancer Res, 2016, 22(1): 79-85. doi: 10.1158/1078-0432.CCR-15-1008 pmid: 26199388
[29]	MANDAIR D, KHAN M S, LOPES A, et al. Prognostic threshold for circulating tumor cells in patients with pancreatic and midgut neuroendocrine tumors[J]. J Clin Endocrinol Metab, 2021, 106(3): 872-882. doi: 10.1210/clinem/dgaa822 pmid: 33180939
[30]	ZAKKA K, NAGY R, DRUSBOSKY L, et al. Blood-based next-generation sequencing analysis of neuroendocrine neoplasms[J]. Oncotarget, 2020, 11(19): 1749-1757. doi: 10.18632/oncotarget.27588 pmid: 32477464
[31]	FINNERTY B M, GRAY K D, MOORE M D, et al. Epigenetics of gastroenteropancreatic neuroendocrine tumors: a clinicopathologic perspective[J]. World J Gastrointest Oncol, 2017, 9(9): 341-353. doi: 10.4251/wjgo.v9.i9.341
[32]	PANARELLI N, TYRYSHKIN K, WONG J J M, et al. Evaluating gastroenteropancreatic neuroendocrine tumors through microRNA sequencing[J]. Endocr Relat Cancer, 2019, 26(1): 47-57. doi: 10.1530/ERC-18-0244
[33]	KLIESER E, URBAS R, SWIERCZYNSKI S, et al. HDAC-linked proliferative miRNA expression pattern in pancreatic neuroendocrine tumors[J]. Int J Mol Sci, 2018, 19(9): 2781. doi: 10.3390/ijms19092781
[34]	MALCZEWSKA A, WITKOWSKA M, WÓJCIK-GIERTUGA M, et al. Prospective evaluation of the NETest as a liquid biopsy for gastroenteropancreatic and bronchopulmonary neuroendocrine tumors: an ENETS center of excellence experience[J]. Neuroendocrinology, 2021, 111(4): 304-319. doi: 10.1159/000508106
[35]	CHIRINDE A. Impact on clinical management of a novel blood-derived liquid biopsy (NETest) in patients with neuroendocrine tumors[C]. ENETS conferenc, 2023.
[36]	BODEI L S, KIDD M S, SINGH A, et al. PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest[J]. Eur J Nucl Med Mol Imaging, 2020, 47(4): 895-906. doi: 10.1007/s00259-019-04601-3
[37]	MALCZEWSKA A, KOS-KUDŁA B, KIDD M, et al. The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors[J]. Adv Med Sci, 2020, 65(1): 18-29. doi: 10.1016/j.advms.2019.10.002
[38]	LE TOURNEAU C, DELORD J P, GONÇALVES A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial[J]. Lancet Oncol, 2015, 16(13): 1324-1334. doi: 10.1016/S1470-2045(15)00188-6 pmid: 26342236
[39]	HORAK P, HEINING C, KREUTZFELDT S, et al. Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers[J]. Cancer Discov, 2021, 11(11): 2780-2795. doi: 10.1158/2159-8290.CD-21-0126 pmid: 34112699
[40]	BOILÈVE A, FARON M, FODIL-CHERIF S, et al. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data[J]. Eur J Cancer, 2023, 186: 122-132. doi: 10.1016/j.ejca.2023.03.024 pmid: 37062210
[41]	GAUDENZI G, DICITORE A, CARRA S, et al. MANAGEMENT OF ENDOCRINE DISEASE: precision medicine in neuroendocrine neoplasms: an update on current management and future perspectives[J]. Eur J Endocrinol, 2019, 181(1): R1-R10. doi: 10.1530/EJE-19-0021
[42]	CAPLIN M E, PAVEL M, ĆWIKŁA J B, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371(3): 224-233. doi: 10.1056/NEJMoa1316158
[43]	RINKE A, MÜLLER H H, SCHADE-BRITTINGER C, et al. Placebo-controlled,double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27(28): 4656-4663. doi: 10.1200/JCO.2009.22.8510
[44]	CHEN L H, JUMAI N, HE Q, et al. The role of quantitative tumor burden based on[⁶⁸Ga]Ga-DOTA-NOC PET/CT in well-differentiated neuroendocrine tumors: beyond prognosis[J]. Eur J Nucl Med Mol Imaging, 2023, 50(2): 525-534. doi: 10.1007/s00259-022-05971-x
[45]	CHI Y, SONG L, LIU W, et al. S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): a randomised, open-label, multicentre phase 2 trial[J]. eClinicalMedicine, 2022, 54: 101667. doi: 10.1016/j.eclinm.2022.101667
[46]	KUNZ P L, CATALANO P J, NIMEIRI H S, et al. A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211)[J]. J Clin Oncol, 2015, 33(15_suppl): TPS4145. doi: 10.1200/jco.2015.33.15_suppl.tps4145
[47]	WANG W, ZHANG Y, PENG Y, et al. A ki-67 index to predict treatment response to the capecitabine/temozolomide regimen in neuroendocrine neoplasms: a retrospective multicenter study[J]. Neuroendocrinology, 2021, 111(8): 752-763. doi: 10.1159/000510159
[48]	CHILDS A, KIRKWOOD A, EDELINE J, et al. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours[J]. Endocr Relat Cancer, 2016, 23(7): 563-570. doi: 10.1530/ERC-16-0099
[49]	PELLAT A, DREYER C, COUFFIGNAL C, et al. Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms[J]. Neuroendocrinology, 2018, 107(1): 24-31. doi: 10.1159/000487237 pmid: 29518779
[50]	ZURITA A J, KHAJAVI M, WU H K, et al. Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours[J]. Br J Cancer, 2015, 112(7): 1199-1205. doi: 10.1038/bjc.2015.73
[51]	LIVERANI C, SPADAZZI C, IBRAHIM T, et al. HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors[J]. Front Endocrinol (Lausanne), 2022, 13: 1045038. doi: 10.3389/fendo.2022.1045038
[52]	CHEN L, WANG W, JIN K, et al. Special issue “The advance of solid tumor research in China”: prediction of Sunitinib efficacy using computed tomography in patients with pancreatic neuroendocrine tumors[J]. Int J Cancer, 2023, 152(1): 90-99. doi: 10.1002/ijc.v152.1
[53]	CHEN H, LI Z, HU Y, et al. Maximum value on arterial phase computed tomography predicts prognosis and treatment efficacy of sunitinib for pancreatic neuroendocrine tumours[J]. Ann Surg Oncol, 2023, 30(5): 2988-2998. doi: 10.1245/s10434-022-12693-9
[54]	YAO J C, PHAN A T, HESS K, et al. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors[J]. Pancreas, 2015, 44(2): 190-197. doi: 10.1097/MPA.0000000000000255
[55]	YAO J, GARG A, CHEN D, et al. Genomic profiling of NETs: a comprehensive analysis of the RADIANT trials[J]. Endocr Relat Cancer, 2019, 26(4): 391-403. doi: 10.1530/ERC-18-0332
[56]	DI NICOLANTONIO F, ARENA S, TABERNERO J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus[J]. J Clin Invest, 2010, 120(8): 2858-2866. doi: 10.1172/JCI37539 pmid: 20664172
[57]	CHANG T M, SHAN Y S, CHU P Y, et al. The regulatory role of aberrant phosphatase and tensin homologue and liver kinase B1 on AKT/mTOR/c-Myc axis in pancreatic neuroendocrine tumors[J]. Oncotarget, 2017, 8(58): 98068-98083. doi: 10.18632/oncotarget.v8i58
[58]	SERRA S, ZHENG L, HASSAN M, et al. The FGFR4-G388R single-nucleotide polymorphism alters pancreatic neuroendocrine tumor progression and response to mTOR inhibition therapy[J]. Cancer Res, 2012, 72(22): 5683-5691. doi: 10.1158/0008-5472.CAN-12-2102 pmid: 22986737
[59]	MPILLA G B, UDDIN M H, AL-HALLAK M N, et al. PAK4-NAMPT dual inhibition sensitizes pancreatic neuroendocrine tumors to everolimus[J]. Mol Cancer Ther, 2021, 20(10): 1836-1845. doi: 10.1158/1535-7163.MCT-20-1105 pmid: 34253597
[60]	ZAKNUN J J, BODEI L, MUELLER-BRAND J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2013, 40(5): 800-816. doi: 10.1007/s00259-012-2330-6
[61]	BODEI L, RAJ N, DO R K, et al. Interim analysis of a prospective validation of 2 blood-based genomic assessments (PPQ and NETest) to determine the clinical efficacy of 177Lu-DOTATATE in neuroendocrine tumors[J]. J Nucl Med, 2023, 64(4): 567-573. doi: 10.2967/jnumed.122.264363
[62]	DESMAISON C, NICCOLI P, OZIEL TAIEB S, et al. Transarterial chemoembolization (TACE) for neuroendocrine liver metastasis (NELM): predictive value of volumetric arterial enhancement (VAE) on baseline MRI[J]. Bull Cancer, 2023, 110(3): 308-319. doi: 10.1016/j.bulcan.2022.12.007 pmid: 36732142
[63]	SAHU S, SCHERNTHANER R, ARDON R, et al. Imaging biomarkers of tumor response in neuroendocrine liver metastases treated with transarterial chemoembolization: can enhancing tumor burden of the whole liver help predict patient survival?[J]. Radiology, 2017, 283(3): 883-894. doi: 10.1148/radiol.2016160838 pmid: 27831830
[64]	LIU Y M, CHEN W C, CUI W, et al. Quantitative pretreatment CT parameters as predictors of tumor response of neuroendocrine tumor liver metastasis to transcatheter arterial bland embolization[J]. Neuroendocrinology, 2020, 110(7/8): 697-704. doi: 10.1159/000504257
[65]	SIGAL D, TARTAR M, XAVIER M, et al. Activity of entrectinib in a patient with the first reported NTRK fusion in neuroendocrine cancer[J]. J Natl Compr Canc Netw, 2017, 15(11): 1317-1322. doi: 10.6004/jnccn.2017.7029
[66]	JONASCH E, DONSKOV F, ILIOPOULOS O, et al. Belzutifan for renal cell carcinoma in von hippel-lindau disease[J]. N Engl J Med, 2021, 385(22): 2036-2046. doi: 10.1056/NEJMoa2103425
[67]	LEE E, RODON J, DEMEURE M, et al. Phase 2, multicenter, open-label basket trial of nab-sirolimus for patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (PRECISION I) (1300)[J]. Gynecol Oncol, 2023, 176: S185.